Refereed review article in scientific journal (A2)
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
List of Authors: Pugliatti Maura, Hartung Hans-Peter, Oreja-Guevara Celia, Pozzilli Carlo, Airas Laura, Alkhawajah Mona, Grigoriadis Nikolaos, Magyari Melinda, Van Wijmeersch Bart, Zakaria Magd, Linker Ralf, Chan Andrew, Vermersch Patrick, Berger Thomas
Publisher: FRONTIERS MEDIA SA
Publication year: 2022
Journal: Frontiers in Immunology
Journal name in source: FRONTIERS IN IMMUNOLOGY
Journal acronym: FRONT IMMUNOL
Article number: 1045101
Volume number: 13
Number of pages: 8
ISSN: 1664-3224
DOI: http://dx.doi.org/10.3389/fimmu.2022.1045101
URL: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1045101/full
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/177267168
It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
Downloadable publication This is an electronic reprint of the original article. |  |
